SCHEMBL7186649

SCHEMBL7186649

Cc1ncc(CO)c(CNC(=O)C(=O)O)c1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.59
ALDH1A1 P00352 4/20 0.59
HPGD P15428 4/20 0.59
HSD17B10 Q99714 1/20 0.59
LMNA P02545 4/20 0.55
GAA P10253 2/20 0.51
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA9 Q16790 3/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
AOX1 Q06278 1/20 0.47
HDAC1 Q13547 2/20 0.46
TRIM24 O15164 1/20 0.46
TRIM33 Q9UPN9 1/20 0.46
PDXK O00764 2/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 3/20 0.39
HTT P42858 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12994391 0.85 KDM4E (0.63) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL18792850 0.83 KDM4E (0.59) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL18792849 0.82 KDM4E (0.58) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL29883611 0.82 KDM4E (0.58) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL7934019 0.82 KDM4E (0.58) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL18763024 0.82 KDM4E (0.58) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL14898738 0.81 GAA (0.56) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL8089106 0.80 KDM4E (0.59) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL9324747 0.80 KDM4E (0.59) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL7242817 0.80 KDM4E (0.73) KDM4EALDH1A1HPGDHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030060490-A1 Method for the treatment and prevention of urinary stone disease NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2003-03-27 US disclosed
US-6521645-B2 Administering pyridoxamine to reduce urinary oxalate concentrations. THE UNIVERSITY OF KANSAS MEDICAL CENTER 2003-02-18 US disclosed
US-20020115694-A1 Methods for the treatment and prevention of urinary stone disease NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-08-22 US disclosed
WO-2002039994-A2 METHODS FOR THE TREATMENT AND PREVENTION OF URINARY STONE DISEASE UNIVERSITY OF KANSAS MEDICAL CENTER (US) 2002-05-23 WO disclosed